AMERSHAM IODINE I 131 TOSITUMOMAB Sample Clauses

AMERSHAM IODINE I 131 TOSITUMOMAB. (a) No later than [*] or the later date agreed in writing by the Parties (such date shall take into account the date upon which the Parties expect Initial Approval for the Product in the Territory and any delays in establishing the radiolabeling facility that are attributable to regulatory agencies and are beyond Amersham's control), Amersham shall establish a radiolabeling facility that, in accordance with all applicable laws and regulations, converts Tositumomab to Amersham Iodine I 131 Tositumomab and supplies all of Amersham's requirements for Iodine I 131 Tositumomab for development and commercial sale in the Territory (the "European Facility"). Amersham may begin supplying Amersham Iodine I 131 Tositumomab at any time prior to [*] or such agreed date. (b) Within [*] days after the Effective Date, Amersham shall provide Corixa with a timetable for the establishment of the European Facility and a copy of Amersham's full plan (rather than a summary thereof) for the manufacture of Amersham Iodine I 131 Tositumomab, which plan shall include the milestones and timelines set forth on Exhibit B hereto. Amersham shall update such timetable and plan semi-annually, provided that any updates or modifications to the milestones and timelines set forth on Exhibit B shall require -------- * Confidential Treatment Requested. Corixa's prior written consent. Corixa may comment on the initial and updated timetables and plans. Amersham's failure to provide the first timetable and the first plan within [*] days after the Effective Date shall constitute a material breach of this Agreement. Amersham shall be responsible for all capital and other expenses related to the establishment of the European Facility and its operation. (c) At the request of Amersham, during the period commencing on the Effective Date and ending [*] after the date determined in accordance with Section 3.3(a), Corixa shall provide reasonable assistance, within Corixa's area of expertise, to help Amersham establish and operate the European Facility. Provision of such assistance shall include, but not be limited to, supply of any Corixa know-how which Amersham may require to the extent such Corixa know-how can be provided to Amersham under applicable agreements with Third Parties. In the event that Amersham requests that Corixa perform work, including providing consultation services, under this Section 3.3(c), Amersham shall reimburse Corixa for all out-of-pocket expenses and personnel expenses (at the a...
AutoNDA by SimpleDocs

Related to AMERSHAM IODINE I 131 TOSITUMOMAB

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • COVID-19 Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • Library Borrowing privileges available without charge. Upon retirement an employee shall be issued a permanent individual library card.

  • Conhecimento da Lingua O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (“Agreement” xx xxxxxx).

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!